Alicia Morgans, MD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (General Urology)
    Ineligible company: 
    Novartis
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/07/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Telix
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/07/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Myriad
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/07/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Lantheus
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/07/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Progenics
    Mitigation strategy: 
    Divest
    Date reviewed: 
    08/07/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Advanced Accelerator Applications
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/07/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Advanced Accelerator Applications
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/07/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Myovant
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/07/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Pfizer
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/07/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    BMS
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/07/2023

Pages

Return to Advances in ADT: Part II: A Guide for Urologists (2023)